Related Experiment Video
Updated: Jun 18, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
'Living drugs' target CD70 in advanced renal tumors
Kilian Wagner1, Peter J Siska1
1Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany.
Abstract:
Cellular therapies against solid tumors face three major barriers: low persistence, insufficient specificity, and high costs. In a recent study, Pal et al. tackle these challenges in kidney cancer by using novel, 'persistence-tuned' allogeneic chimeric antigen receptor (CAR) T cells directed against a stable antigen.
Insights
Researchers developed novel
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Solid tumors, including kidney cancer, present significant challenges for cellular therapies.
- Existing treatments often suffer from limited T cell persistence, specificity, and high costs.
Purpose of the Study:
- To overcome major barriers in cellular therapy for solid tumors.
- To develop enhanced chimeric antigen receptor (CAR) T cells for kidney cancer treatment.
Main Methods:
- Utilized allogeneic CAR T cells engineered for 'persistence-tuning'.
- Targeted a stable antigen specific to kidney cancer cells.
Main Results:
- Demonstrated a novel approach to enhance CAR T cell efficacy.
- Addressed key limitations of current cellular therapies in preclinical models.
Conclusions:
- 'Persistence-tuned' allogeneic CAR T cells show promise for kidney cancer.
- This strategy offers a potential solution to improve cellular therapy outcomes.
